- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04788615
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)
Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized (1:1), open-label, rater-blind, multi-center, prospective, parallel-arm, active comparator study which will consist of 15 months treatment period and a 6 months observational safety extension period, for patients who withdraw ofatumumab for any reason, in 186 total patients with early relapsing multiple sclerosis (RMS) RMS patients are patients who are newly diagnosed or have never been on active treatment at the time of study entry with ≤ 5 years from first MS symptoms.
There is a screening period and patients are randomized to either ofatumumab or first line DMT at baseline. Patients will be treated until the end of study (EOS) or for a maximum duration of 15 months. Patients who prematurely discontinue study drug or comparator will have their end of treatment (EOT) visit and assessments at the time of discontinuation. After ofatumumab or the standard of care comparator (DMT) discontinuation, patients may initiate alternative MS therapy according to local standard of care, if clinically indicated.
Patients who for any reason withdraw from ofatumumab during treatment will be invited to participate in the observational extension safety period for 6 months or until patient re-starts MS treatment with a new DMT treatment. During this period, clinical efficacy after ofatumumab withdrawal will be assessed.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Amiens, France, 80054
- Recruiting
- Novartis Investigative Site
-
Bordeaux Cedex, France, 33076
- Recruiting
- Novartis Investigative Site
-
Clermont-Ferrand Cedex 1, France, 63003
- Recruiting
- Novartis Investigative Site
-
Creteil, France, 94010
- Recruiting
- Novartis Investigative Site
-
Gonesse, France, 95500
- Recruiting
- Novartis Investigative Site
-
Grenoble, France, 38042
- Recruiting
- Novartis Investigative Site
-
Lille Cedex, France, 59037
- Recruiting
- Novartis Investigative Site
-
Montpellier, France, 34295
- Recruiting
- Novartis Investigative Site
-
Nice, France, 06202
- Recruiting
- Novartis Investigative Site
-
Nimes, France, 30029
- Recruiting
- Novartis Investigative Site
-
Poissy, France, 78303
- Recruiting
- Novartis Investigative Site
-
Rennes Cedex, France, 35033
- Recruiting
- Novartis Investigative Site
-
Strasbourg, France, 67098
- Recruiting
- Novartis Investigative Site
-
Suresnes, France, 92150
- Recruiting
- Novartis Investigative Site
-
-
Bayonne Cedex
-
Bayonne, Bayonne Cedex, France, 64109
- Recruiting
- Novartis Investigative Site
-
-
Cedex 1
-
Nantes, Cedex 1, France, 44093
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bayreuth, Germany, 95445
- Recruiting
- Novartis Investigative Site
-
Berlin, Germany, 13353
- Recruiting
- Novartis Investigative Site
-
Berlin, Germany, 12101
- Recruiting
- Novartis Investigative Site
-
Bielefeld, Germany, 33647
- Active, not recruiting
- Novartis Investigative Site
-
Dortmund, Germany, 44137
- Recruiting
- Novartis Investigative Site
-
Erbach, Germany, 64711
- Recruiting
- Novartis Investigative Site
-
Frankfurt, Germany, 60590
- Recruiting
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Recruiting
- Novartis Investigative Site
-
Kassel, Germany, 34121
- Withdrawn
- Novartis Investigative Site
-
Koeln, Germany, 50937
- Recruiting
- Novartis Investigative Site
-
Siegen, Germany, 57076
- Recruiting
- Novartis Investigative Site
-
Ulm, Germany, 89081
- Withdrawn
- Novartis Investigative Site
-
Ulm, Germany, 89073
- Recruiting
- Novartis Investigative Site
-
Westerstede Oldenburg, Germany, 26655
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Napoli, Italy, 80131
- Recruiting
- Novartis Investigative Site
-
-
BS
-
Montichiari, BS, Italy, 25018
- Recruiting
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20132
- Recruiting
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00133
- Recruiting
- Novartis Investigative Site
-
Roma, RM, Italy, 00189
- Recruiting
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Italy, 10043
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28040
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28009
- Recruiting
- Novartis Investigative Site
-
Valencia, Spain, 46026
- Recruiting
- Novartis Investigative Site
-
Zaragoza, Spain, 50009
- Recruiting
- Novartis Investigative Site
-
-
Andalucia
-
Malaga, Andalucia, Spain, 29010
- Recruiting
- Novartis Investigative Site
-
Sevilla, Andalucia, Spain, 41009
- Recruiting
- Novartis Investigative Site
-
-
Cataluna
-
Salt, Cataluna, Spain, 17190
- Recruiting
- Novartis Investigative Site
-
-
Galicia
-
Santiago De Compostela, Galicia, Spain, 15706
- Recruiting
- Novartis Investigative Site
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Recruiting
- Novartis Investigative Site
-
-
Vizcaya
-
Baracaldo, Vizcaya, Spain, 48903
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Exeter, United Kingdom, EX2 5DW
- Withdrawn
- Novartis Investigative Site
-
Glasgow, United Kingdom, G51 4TF
- Withdrawn
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Written informed consent obtained before any assessment
- Male/female patients, 18 through 55 (inclusive) years of age.
- Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018).
- Relapsing MS: relapsing-course (RMS), as defined by Lublin et al 2014.
- Treatment Naïve patients, ≤ 5 years since first MS symptom.
- EDSS score 0-4.0 (inclusive).
- Patient must be suitable to be treated with one of first line self-administered DMT-physician's choice (glatiramer acetate, IFNs, teriflunomide, DMF, diroximel fumarate according to EMA SmPC) or ofatumumab depending on randomization and physician's choice
- At least 1 relapse or 1 Gd+ enhanced lesion on T1 in 1 year prior to Screening.
- Able to obtain MRI assessment.
- Neurologically stable within 1 month prior to first study drug administration Exclusion Criteria
- Diseases other than multiple sclerosis responsible for the clinical or MRI presentation
- Progressive MS phenotypes: Patients with primary progressive MS (Polman et al 2011) or SPMS (Lublin et al 2014).
- Use of other experimental or investigational drugs at the time of enrollment (Screening) or within the prior 30 days, or 5 elimination half-lives, or until the expected pharmacodynamics effect has returned to baseline, whichever is longer
- Relapse between Screening and Baseline visits
- Pregnancy or breastfeeding
- Patients suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the Investigator
Women of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception (methods that result in less than 1% pregnancy rates) while receiving ofatumumab and for 6 months after the last administration. The requirements for contraception for the comparators should also be taken into consideration according to their SmPC.
Highly effective methods of contraception include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
(Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success.) - Use of combined, estrogen and progesterone containing (oral, intravaginal, transdermal), hormonal methods of contraception or use of progesterone-only (oral, injectable, implantable) hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of childbearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF.
- Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g. rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or with immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency)
- Patients with an active infection (bacterial, fungal, or viral like hepatitis, HIV or COVID), until the infection is resolved. Where local regulation requires it, Sars-Cov-19 must be ruled out by the PCR test.
- Patients with neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML
Positive results at Screening for serological markers for hepatitis (H) B and C indicating acute or chronic infection:
- Hepatitis B virus (HBV) screening should be performed before initiation of treatment.
At a minimum, screening should include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) testing. These can be complemented with other appropriate markers as per local guidelines. Patients with positive hepatitis B serology (either HBsAg or HBcAb) should consult a liver disease expert before the start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.
- Hepatitis C risk must be ruled out via anti-HC IgG (if positive IgG, HCV-RNA PCR will be performed and if negative, patient can be enrolled) NOTE: If the Investigator suspects false positive hepatitis serology results such as an antibody pattern indicating acute hepatitis infection but no corresponding elevated liver enzymes and no signs or symptoms of liver disease, an infectious disease expert may be consulted. In the case the patient has a record of vaccination including HB, and there is no evidence of acute or chronic hepatitis infection (confirmed by an infectious disease expert), the Investigator must document (in source data and as a comment in the electronic Case Report Form (eCRF) that the serology results are considered false positive and may then enroll the subject.
- Have received any live or live-attenuated vaccines within 4 weeks prior to first study drug administration
- Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate or comply with the study procedures
Any of the following conditions or treatments that may impact the safety of the patient:
- History of, or current, significant cardiac disease including cardiac failure (NYHA functional class II-IV), myocardial infarction (within 6 months prior to screening), unstable angina (within 6 months prior to screening), transient ischemic attack (within 6 months prior to screening), stroke, cardiac arrhythmias requiring treatment or uncontrolled arterial hypertension
- Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia and clinically significant second or third degree AV block without a pacemaker on screening electrocardiogram (ECG)
- History of or active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis
- Patients with asthma requiring regular treatment with oral steroids
- Severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease
- Patients with severe renal impairment (glomerular filtration rate < 30 ml/min/1.73 m2)
- Any medically unstable condition as determined by the Investigator
Any of the following abnormal laboratory values prior to first study drug administration:
- Total bilirubin greater than 3 times upper limit of normal (ULN) range, unless in the context of Gilbert's syndrome
- Alkaline phosphatase (ALP) greater than 5 times the ULN range
- Serum IgG < 500mg/dL (according to central laboratory range)
- Any other clinically significant laboratory assessment as determined by the Investigator (e.g. significant anemia, neutropenia, thrombocytopenia, signs of impaired bone marrow function)
- Patients with severe hypoproteinemia e.g. in nephrotic syndrome
Patients with any of the following neurologic/psychiatric disorders prior to first study drug administration: - Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the Columbia- Suicide Severity Rating Scale (CSSRS) if this ideation occurred in the past 6 months OR
- "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self- Injurious Behavior" (item also included in the Suicidal Behavior section) if this behavior occurred in the past 2 years.
- History of hypersensitivity to the study drug or any of the excipients or to drugs of similar chemical classes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ofatumumab
Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.
|
20mg Subcutaneous injection
Other Names:
|
Active Comparator: First line DMT
|
any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with no evidence of disease activity (NEDA-3)
Time Frame: Baseline to 15 month
|
NEDA-3 (yes/no) is defined as:
|
Baseline to 15 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of relapses
Time Frame: Baseline to Month 15
|
Number of relapses will be summarized descriptively
|
Baseline to Month 15
|
Annual relapse rate
Time Frame: Baseline to Month 15
|
Annual relapse rate will be analyzed by treatment group using negative binomial regression model with log-link and patient's time in study will be used as an offset.
|
Baseline to Month 15
|
Percentage of relapse-free patients and proportion of relapse free patients with MRI activity free
Time Frame: Month 3, Month 9 and Month 15
|
Proportion of relapse-free patients and proportion of relapse-free patients with MRI activity free at Month 3, 9 and 15 will be summarized descriptively at each timepoint.
|
Month 3, Month 9 and Month 15
|
Time to 3 month Confirmed Disability Worsening (CDW) and time to 6-month Confirmed Disability Worsening (CDW)
Time Frame: Baseline to Month 3 and to Month 6
|
Time to 3 month Confirmed Disability Worsening (CDW) and time to 6-month CDW will be assessed by EDSS (Expanded disability status scale) score
|
Baseline to Month 3 and to Month 6
|
Change in expanded disability status scale (EDSS)
Time Frame: Baseline to Month 15
|
Change in expanded disability status scale (EDSS) from baseline to end of study will be summarized descriptively based on the expanded disability status scale (EDSS) score
|
Baseline to Month 15
|
Percentage of disability-progression free patients
Time Frame: Baseline to Month 15
|
Proportion of disability-progression free patients at end of study will be summarized descriptively
|
Baseline to Month 15
|
Number of Gd+ T1 lesions of brain
Time Frame: Baseline to Month 15
|
Number of Gd+ T1 lesions of brain will be summarized descriptively.
|
Baseline to Month 15
|
The number and percentage of patients with Treatment emergent adverse events (TEAE) or adverse events reports
Time Frame: Baseline to Month 15 and 6 months safety follow-up
|
Adverse will be collected at each patients visit including any clinically significant safety assessments determined to be an adverse event by the investigator
|
Baseline to Month 15 and 6 months safety follow-up
|
Volume of Gd+ T1 lesions of brain
Time Frame: Baseline to Month 15
|
Volume of Gd+ T1 lesions of brain will be summarized descriptively.
|
Baseline to Month 15
|
Number of new/enlarging T2 lesions of brain
Time Frame: Baseline to Month 15
|
Number of new/enlarging T2 lesions of brain will be summarized descriptively.
|
Baseline to Month 15
|
Volume of new enlarging T2 lesions of brain
Time Frame: Baseline to Month 15
|
Volume of new enlarging T2 lesions of brain will be summarized descriptively.
|
Baseline to Month 15
|
Mean time to first relapse
Time Frame: Baseline to Month 15
|
Mean time to first relapse will be summarized descriptively
|
Baseline to Month 15
|
Percentage of SAEs, and SAEs with hospitalizations
Time Frame: Baseline to Month 15 and 6 months safety follow-up
|
Proportion of SAEs, and SAEs with hospitalizations between ofatumumab 20 mg s.c. and first line self-administered DMTs
|
Baseline to Month 15 and 6 months safety follow-up
|
Percentage of treatment compliance of participants
Time Frame: Baseline to Month 15
|
Treatment compliance will be assessed by review of participant diary entries and counts of treatment (dispensed and returned)
|
Baseline to Month 15
|
Percentage of patient with AEs
Time Frame: Baseline to Month 15 and 6 months safety follow-up
|
Proportion of patients with adverse events, including injection related reactions
|
Baseline to Month 15 and 6 months safety follow-up
|
Percentage of withdrawn patients
Time Frame: Baseline to Month 15
|
Proportion of patients who withdrew due to abnormal lab values
|
Baseline to Month 15
|
Percentage of treatment discontinuation or interruptions
Time Frame: Baseline to Month 15
|
Proportion of treatment discontinuation or interruptions for safety/ tolerability reason
|
Baseline to Month 15
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Adjuvants, Immunologic
- Interferons
- Interferon beta-1a
- Ofatumumab
- Interferon-beta
- Glatiramer Acetate
- (T,G)-A-L
- Dimethyl Fumarate
- Teriflunomide
Other Study ID Numbers
- COMB157G3301
- 2020-004505-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Ofatumumab
-
GlaxoSmithKlineTerminatedArthritis, RheumatoidUnited States, Denmark, Hungary, United Kingdom, Poland
-
GlaxoSmithKlineCompletedMultiple SclerosisUnited States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsCompleted
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic and Lymphoma, FollicularJapan
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic
-
Novartis PharmaceuticalsRecruitingMultiple Sclerosis (MS)France
-
Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingLeukemia, Lymphoblastic, ChronicItaly